DEF 14A: Pasithea Therapeutics Sets Date for Virtual Annual Meeting, Seeks Stockholder Approval on Key Proposals

Pasithea Therapeutics will hold its annual stockholder meeting virtually on June 26, 2024, to vote on the election of a director and the ratification of its independent auditor.

Summary

• Pasithea Therapeutics Corp. will hold its Annual Meeting of Stockholders virtually on June 26, 2024, at 9:00 AM Eastern Time.
• Stockholders will vote on the election of Dr. Emer Leahy as a director and the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is April 29, 2024.
• The meeting will be conducted via live webcast, allowing stockholders to participate virtually.
• Stockholders are encouraged to submit their proxies as soon as possible, even if they plan to attend the virtual meeting.
• Proxies can be submitted by mail, telephone, or internet.
• The Board recommends voting for the election of the director nominee and for the ratification of the appointment of Marcum.
• A quorum requires the presence of 33 1/3% of all shares entitled to vote.
• Director nominees are elected by a plurality of the votes cast.
• Ratification of the accounting firm requires the affirmative vote of a majority of the votes cast.
• The company's proxy materials, including the Proxy Statement and Annual Report on Form 10-K, are available online at www.proxyvote.com.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The information provided is factual and objective, with no explicit positive or negative sentiment expressed. The company is following standard corporate governance procedures.

Positives

• The virtual format of the Annual Meeting allows for broader stockholder participation and reduces costs.
• The Board is actively engaged in risk oversight through various committees.
• The company has adopted a written code of business conduct and ethics.
• The company has policies in place to review and approve related person transactions.
• The company offers indemnification agreements for its directors and executive officers.
• The company has an anti-hedging policy in place for directors and executives.

Negatives

• Prof. Lawrence Steinman was deemed not independent due to a transaction with Alpha-5 integrin, LLC.
• The company incurred approximately $0.3 million in payments to PsychoGenics, Inc., where Dr. Emer Leahy is the CEO and a less than 5% owner, for preclinical studies.
• The company's stock options have a weighted average exercise price of $32.38.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or control.
• The limitation of liability and indemnification provisions in the Certificate and Bylaws may discourage stockholders from bringing lawsuits against directors.
• The company's reliance on key personnel and the potential loss of their services could negatively impact the business.
• The company's success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.

Future Outlook

The company is seeking stockholder approval for the election of a director and the ratification of its independent auditor, which are standard corporate governance procedures.

Industry Context

This is a standard proxy statement for a publicly traded company, covering routine matters such as director elections and auditor ratification. The details on executive compensation and related-party transactions provide insights into the company's governance practices.

Comparison to Industry Standards

• The executive compensation packages appear to be within the typical range for small-cap biopharmaceutical companies.
• The director compensation structure, including retainers and equity awards, is consistent with industry norms.
• The company's corporate governance practices, such as having an audit committee and a code of ethics, align with Nasdaq listing requirements and best practices.
• The disclosure of related-party transactions is in line with SEC regulations and provides transparency to investors.
• Comparable companies in the biopharmaceutical industry include First Wave BioPharma, Inc. and Biophytis SA, where the CFO, Daniel Schneiderman, previously held positions.

Related Party Transactions

• In April 2023, Pasithea entered into a contract with PsychoGenics, Inc. for preclinical studies, with aggregate payments totaling approximately $0.3 million; Dr. Emer Leahy, a Pasithea board member, is the CEO and a less than 5% owner of PsychoGenics.
• On June 21, 2022, Pasithea acquired Alpha-5 Integrin, LLC from PD Joint Holdings, LLC Series 2016-A and Prof. Lawrence Steinman, issuing 163,044 shares of Common Stock and warrants for 50,000 shares; Prof. Steinman, Pasithea's Executive Chairman, was a 20% owner of Alpha-5 at the time of the transaction.
• Prof. Lawrence Steinman receives $25,000 per quarter for consulting services under the Steinman Consulting Agreement.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will influence the company's governance and financial oversight.
• The election of directors will shape the strategic direction of the company.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.
• Executive compensation decisions impact shareholder value and employee motivation.

Next Steps

• Stockholders to review the proxy materials and submit their votes.
• The company to hold the Annual Meeting on June 26, 2024.
• The company to announce the voting results in a filing with the SEC on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, Pasithea Therapeutics, Stockholders, Marcum LLP, Board of Directors